Stressed-out cancers may provide drug target

December 01, 2014

Research at the University of Adelaide has discovered cancer cells may be particularly susceptible to metabolic stress - opening the way for new targeted therapy that won't harm normal cells.

The researchers showed that chromosomal instability - which is a hallmark of rapidly dividing cancer cells - makes them stressed and vulnerable to mild metabolic disruption. Metabolism is the normal process by which the body turns food into energy.

"A common problem in treating cancers is that they don't respond to chemotherapy, or they respond for a while, but then come back," says lead author Dr Stephen Gregory, Senior Postdoctoral Fellow with the University's School of Molecular and Biomedical Sciences.

"One reason this happens is because a tumour is usually not made up of identical cells but rather a diverse population of cells that changes all the time, losing and gaining chromosomes as they divide - so-called chromosomal instability. Sooner or later they change enough to be able to resist chemotherapy drugs.

"Our research has shown that chromosomal instability has some consequences for cells - they get stressed, and it only takes a small metabolic push to kill them."

Current chemotherapy is also very toxic to all dividing cells, particularly affecting cells in hair follicles, the gut lining and blood, often causing hair loss, pain and making patients unwell.

"We need to find ways to target cancer cells without affecting other normal dividing cells," says Dr Gregory.

The researchers induced chromosomal instability in small experimental flies, Drosophila, and found that the unstable cells were "on the edge" of how much stress they could tolerate.

"This is significant because a change in metabolism is something people cope with very well normally," says Dr Gregory. "That means that we hope to be able to develop treatments that have no side effects on patients, but are able to kill off the unstable tumour cells that cause relapses."

Dr Gregory says this may give some validity to theories of alternative treatments such as going on a radical diet.

"People who have advanced cancer which isn't responding to chemotherapy often try a range of different treatments such as a radical diet in the hope it may help," he says. "In some situations, it may in fact work; but we hope to be able to point the way to a more targeted approach - finding the most appropriate steps for intervention in the metabolic process that will give the best results."
-end-
The research has been published in the journal Oncogene. It is funded by the National Health and Medical Research Council and continues with a recent NHMRC project grant of $593,000.

Media Contact

Dr Stephen Gregory
NHMRC Senior Postdoctoral Fellow
School of Molecular and Biomedical Sciences
The University of Adelaide
Phone: +61 8 8313 7536
Mobile: +61 466 987 583
stephen.gregory@adelaide.edu.au

Robyn Mills
Media and Communications Officer
The University of Adelaide
Phone: +61 8 8313 6341
Mobile: +61 410 689 084
robyn.mills@adelaide.edu.au

University of Adelaide

Related Chemotherapy Articles from Brightsurf:

Chemotherapy is used to treat less than 25% of people with localized sarcoma
UCLA researchers have found that chemotherapy is not commonly used when treating adults with localized sarcoma, a rare type of cancer of the soft tissues or bone.

Starved cancer cells became more sensitive to chemotherapy
By preventing sugar uptake, researchers succeeded in increasing the cancer cells' sensitivity to chemotherapeutic treatment.

Vitamin D could help mitigate chemotherapy side effects
New findings by University of South Australia researchers reveal that Vitamin D could potentially mitigate chemotherapy-induced gastrointestinal mucositis and provide relief to cancer patients.

Less chemotherapy may have more benefit in rectal cancer
GI Cancers Symposium: Colorado study of 48 patients with locally advanced rectal cancer receiving neoadjuvant chemotherapy, found that patients receiving lower-than-recommended doses in fact saw their tumors shrink more than patients receiving the full dose.

Male fertility after chemotherapy: New questions raised
Professor Delb├Ęs, who specializes in reproductive toxicology, conducted a pilot study in collaboration with oncologists and fertility specialists from the McGill University Health Centre (MUHC) on a cohort of 13 patients, all survivors of pediatric leukemia and lymphoma.

'Combo' nanoplatforms for chemotherapy
In a paper to be published in the forthcoming issue in NANO, researchers from Harbin Institute of Technology, China have systematically discussed the recent progresses, current challenges and future perspectives of smart graphene-based nanoplatforms for synergistic tumor therapy and bio-imaging.

Nanotechnology improves chemotherapy delivery
Michigan State University scientists have invented a new way to monitor chemotherapy concentrations, which is more effective in keeping patients' treatments within the crucial therapeutic window.

Novel anti-cancer nanomedicine for efficient chemotherapy
Researchers have developed a new anti-cancer nanomedicine for targeted cancer chemotherapy.

Ending needless chemotherapy for breast cancer
A diagnostic test developed at The University of Queensland might soon determine if a breast cancer patient requires chemotherapy or would receive no benefit from this gruelling treatment.

A homing beacon for chemotherapy drugs
Killing tumor cells while sparing their normal counterparts is a central challenge of cancer chemotherapy.

Read More: Chemotherapy News and Chemotherapy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.